Search research articles
Contact Us
Filters
Showing results (1-10 of 110) with videos related to
Page
of 11
Sort By:
Therapeutic Advances in Neurological Disorders
|
March 1, 2021
Health economics of disease-modifying therapy for multiple sclerosis in the United States
Daniel M Hartung
Current Neurology and Neuroscience Reports
|
May 5, 2021
Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA
Daniel M Hartung
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
August 17, 2017
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
Daniel M Hartung
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
February 10, 2009
Overview of clinical research design
Daniel M Hartung, Daniel Touchette
Neurology
|
April 6, 2026
Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties
Dennis Bourdette, Daniel M Hartung
JAMA Neurology
|
August 27, 2019
Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis
Daniel M Hartung, Dennis Bourdette
Neurology. Clinical Practice
|
January 8, 2025
Industry Payments and Branded Glatiramer Acetate Prescribing in the US Medicare Program
Daniel M Hartung, Sheila Markwardt, Dennis Bourdette
Health Informatics Journal
|
June 5, 2024
Effect of integration of prescription drug monitoring program data in the electronic health record on queries by primary care providers
Daniel M Hartung, Steven Z Kassakian, Michelle A Hendricks
Pain Medicine (Malden, Mass.)
|
October 11, 2020
Exploring Patient Perceptions of Opioid Treatment Agreements in a Community Health Center Environment
Adriane N Irwin, Natalea Braden-Suchy, Daniel M Hartung
JAMA Internal Medicine
|
April 4, 2018
Uses of H.P. Acthar Gel in the Clinical Setting-Reply
Daniel M Hartung, Dennis N Bourdette, David M Cohen
Page
of 11
Search research articles
Search
Showing results (1-10 of 110) with videos related to
Sort By:
Page
of 11
Therapeutic Advances in Neurological Disorders
|
March 1, 2021
Health economics of disease-modifying therapy for multiple sclerosis in the United States
Daniel M Hartung
Current Neurology and Neuroscience Reports
|
May 5, 2021
Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA
Daniel M Hartung
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
August 17, 2017
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA
Daniel M Hartung
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
February 10, 2009
Overview of clinical research design
Daniel M Hartung, Daniel Touchette
Neurology
|
April 6, 2026
Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties
Dennis Bourdette, Daniel M Hartung
JAMA Neurology
|
August 27, 2019
Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis
Daniel M Hartung, Dennis Bourdette
Neurology. Clinical Practice
|
January 8, 2025
Industry Payments and Branded Glatiramer Acetate Prescribing in the US Medicare Program
Daniel M Hartung, Sheila Markwardt, Dennis Bourdette
Health Informatics Journal
|
June 5, 2024
Effect of integration of prescription drug monitoring program data in the electronic health record on queries by primary care providers
Daniel M Hartung, Steven Z Kassakian, Michelle A Hendricks
Pain Medicine (Malden, Mass.)
|
October 11, 2020
Exploring Patient Perceptions of Opioid Treatment Agreements in a Community Health Center Environment
Adriane N Irwin, Natalea Braden-Suchy, Daniel M Hartung
JAMA Internal Medicine
|
April 4, 2018
Uses of H.P. Acthar Gel in the Clinical Setting-Reply
Daniel M Hartung, Dennis N Bourdette, David M Cohen
Page
of 11